BiotechTube

Secukinumab

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spondylarthropathies

Conditions

Spondylarthropathies

Trial Timeline

Mar 1, 2014 → Oct 1, 2017

NCT ID
NCT03358134

About Secukinumab

Secukinumab is a phase 3 stage product being developed by Novartis for Spondylarthropathies. The current trial status is completed. This product is registered under clinical trial identifier NCT03358134. Target conditions include Spondylarthropathies.

What happened to similar drugs?

2 of 2 similar drugs in Spondylarthropathies were approved

Approved (2) Terminated (1) Active (0)
✅EtanerceptPfizerApproved
✅MethotrexateOrion CorporationApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT05583604Pre-clinicalActive
NCT07243782Pre-clinicalRecruiting
NCT06751238Phase 1Recruiting
NCT06905288Pre-clinicalRecruiting
NCT06331312Phase 3Recruiting
NCT06130540Phase 1Completed
NCT05569174Phase 3Completed
NCT05232864Phase 3Terminated
NCT05206591Phase 3Withdrawn
NCT04894890Pre-clinicalCompleted
NCT04717466ApprovedCompleted
NCT05677542Pre-clinicalCompleted
NCT05513014Pre-clinicalCompleted
NCT05320159Pre-clinicalCompleted
NCT05650060Pre-clinicalCompleted
NCT03866317Phase 2Withdrawn
NCT03769168Phase 3Completed
NCT03791060Phase 2Terminated
NCT03440736ApprovedCompleted
NCT03307447ApprovedUNKNOWN

Competing Products

3 competing products in Spondylarthropathies

See all competitors
ProductCompanyStageHype Score
EtanerceptPfizerApproved
43
MethotrexateOrion CorporationApproved
32
etoricoxib + Other COX-2 inhibitor + nsNSAIDsOrganonPre-clinical
20